Cyclophosphamide

Generic Name: Cyclophosphamide

Brand Names: Procytox

Drug Type: Small Molecule

Chemical Formula: C_₇H_₁₅Cl_₂N_₂O_₂P

CAS Number: 50-18-0

Unique Ingredient Identifier: 6UXW23996M

Background: Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.

Indication: Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma

Associated Therapies: -

Clinical Trials

Randomized Study Comparing Pre- and Postoperative vs. Conventional Adjuvant Treatment in Receptor-negative Patients

Phase 3

Completed

Conditions: Early Stage Breast Cancer

Interventions: Drug: Cyclophosphamide
Drug: Methotrexate
Drug: Fluorouracil
Drug: Epirubicin
Other: Surgery

First Posted Date: 2006-04-03

Last Posted Date: 2020-10-14

Lead Sponsor: Austrian Breast & Colorectal Cancer Study Group

Target Recruit Count: 429

Registration Number: NCT00309569

Randomized Study Comparing CMF and Goserelin + Tamoxifen in Premenopausal Receptor-positive Patients

Phase 3

Completed

Conditions: Early-stage Breast Cancer

Interventions: Drug: Cyclophosphamide
Drug: Goserelin
Drug: Tamoxifen
Drug: Methotrexate
Drug: Fluorouracil implant

First Posted Date: 2006-04-03

Last Posted Date: 2023-06-29

Lead Sponsor: Austrian Breast & Colorectal Cancer Study Group

Target Recruit Count: 1099

Registration Number: NCT00309478

Combination Chemotherapy and Rituximab in Treating Patients With Chronic Lymphocytic Leukemia (CLL) That Did Not Respond to Fludarabine, CLL With Autoimmune Haemolytic Anemia (AIHA) or Richter's Transformation (RT)

Phase 2

Completed

Conditions: Chronic Lymphocytic Leukemia

First Posted Date: 2006-04-03

Last Posted Date: 2016-10-03

Lead Sponsor: German CLL Study Group

Target Recruit Count: 75

Registration Number: NCT00309881

Locations: 🇩🇪
Kreiskrankenhaus, Bad Hersfeld, Germany
🇩🇪
Internistische Onkologische Praxis - Kronach, Kronach, Germany
🇩🇪
Universitaetsklinikum Essen, Essen, Germany

and more 15 locations

AZD2171 and Combination Chemotherapy in Treating Women With Locally Advanced Breast Cancer

Not Applicable

Completed

Conditions: Breast Cancer

First Posted Date: 2006-04-03

Last Posted Date: 2013-06-20

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 33

Registration Number: NCT00310089

Locations: 🇺🇸
Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States
🇺🇸
Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States

IMPROVE: Mycophenolate Mofetil Versus Azathioprine for Maintenance Therapy in ANCA Associated Systemic Vasculitis

Phase 3

Terminated

Conditions: ANCA Associated Systemic Vasculitis Including Wegener's
Granulomatosis and Microscopic Polyangiitis and
Renal Limited Vasculitis

First Posted Date: 2006-03-28

Last Posted Date: 2006-04-10

Lead Sponsor: Assistance Publique - Hôpitaux de Paris

Target Recruit Count: 160

Registration Number: NCT00307645

Locations: 🇬🇧
Addenbrooke's Hospital - Departement of Medecine, Cambridge, United Kingdom
🇫🇷
Hopital Cochin, Paris, France

Non-Myeloablative Conditioning for Unrelated Donor Umbilical Cord Blood Transplant

Phase 2

Completed

Conditions: Leukemia
Lymphoma
Myelodysplastic Syndromes
Myeloproliferative Disorders

Interventions: Biological: anti-thymocyte globulin
Drug: cyclophosphamide
Drug: Fludarabine
Drug: mycophenolate mofetil
Procedure: umbilical cord blood transplantation
Radiation: total body irradiation
Drug: Sirolimus

First Posted Date: 2006-03-22

Last Posted Date: 2020-11-19

Lead Sponsor: Masonic Cancer Center, University of Minnesota

Target Recruit Count: 295

Registration Number: NCT00305682

Locations: 🇺🇸
Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States

Vaccine Therapy, Cyclophosphamide, and Cetuximab in Treating Patients With Metastatic or Locally Advanced Pancreatic Cancer

Phase 2

Completed

Conditions: Pancreatic Cancer

Interventions: Drug: Cetuximab
Biological: Pancreatic tumor vaccine
Drug: Cyclophosphamide

First Posted Date: 2006-03-22

Last Posted Date: 2020-02-19

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Target Recruit Count: 60

Registration Number: NCT00305760

Locations: 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States

Radiation Therapy and Combination Chemotherapy in Treating Young Patients With Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Ependymoma

Not Applicable

Completed

Conditions: Brain and Central Nervous System Tumors

First Posted Date: 2006-03-17

Last Posted Date: 2014-01-28

Lead Sponsor: Universitätsklinikum Hamburg-Eppendorf

Target Recruit Count: 567

Registration Number: NCT00303810

Locations: 🇩🇪
University Medical Center Hamburg - Eppendorf, Hamburg, Germany

Allogeneic Bone Marrow Transplantation Using Less Intensive Therapy

Phase 2

Terminated

Conditions: Kidney Cancer
Leukemia
Lymphoma
Multiple Myeloma
Plasma Cell Neoplasm
Myelodysplastic Syndromes

Interventions: Biological: anti-thymocyte globulin
Drug: cyclophosphamide
Drug: cyclosporine
Drug: fludarabine
Drug: mycophenolate mofetil
Procedure: stem cell transplantation
Radiation: total body irradiation
Drug: filgrastim

First Posted Date: 2006-03-17

Last Posted Date: 2020-05-12

Lead Sponsor: Masonic Cancer Center, University of Minnesota

Target Recruit Count: 342

Registration Number: NCT00303719

Locations: 🇺🇸
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States

Donor Natural Killer Cells and Aldesleukin in Treating Patients w/High Risk AML Undergoing Donor Stem Cell Transplant

Phase 1

Completed

Conditions: Acute Myelogenous Leukemia

Interventions: Biological: aldesleukin
Biological: natural killer cells
Drug: fludarabine phosphate
Biological: Thymoglobulin
Procedure: allogeneic hematopoietic stem cell transplantation
Radiation: total body irradiation
Drug: cyclophosphamide
Drug: Cyclosporin A

First Posted Date: 2006-03-17

Last Posted Date: 2017-12-28

Lead Sponsor: Masonic Cancer Center, University of Minnesota

Target Recruit Count: 50

Registration Number: NCT00303667

Locations: 🇺🇸
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy